about
WWOX, the common chromosomal fragile site, FRA16D, cancer geneA protein-domain microarray identifies novel protein-protein interactions.Variable expression of cysteinyl leukotriene type I receptor splice variants in asthmatic females with different promoter haplotypes.Basal keratin expression in breast cancer by quantification of mRNA and by immunohistochemistry.Diverse effect of WWOX overexpression in HT29 and SW480 colon cancer cell lines.Molecular analysis of WWOX expression correlation with proliferation and apoptosis in glioblastoma multiformeCentral Nervous System and Peripheral Expression of CCL19, CCL21 and Their Receptor CCR7 in Experimental Model of Multiple SclerosisThe whole-genome expression analysis of peripheral blood mononuclear cells from aspirin sensitive asthmatics versus aspirin tolerant patients and healthy donors after in vitro aspirin challenge.Alteration of WWOX in human cancer: a clinical view.Does vimentin help to delineate the so-called 'basal type breast cancer'?WWOX, the tumour suppressor gene affected in multiple cancers.Common profiles of Notch signaling differentiate disease-free survival in luminal type A and triple negative breast cancer.The influence of the WWOX gene on the regulation of biological processes during endometrial carcinogenesis.The role of WWOX tumor suppressor gene in the regulation of EMT process via regulation of CDH1-ZEB1-VIM expression in endometrial cancer.Cell-based assay for low- and high-scale screening of the Wnt/β-catenin signaling modulators.WWOX modulates the gene expression profile in the T98G glioblastoma cell line rendering its phenotype less malignantComparative effects of retinoic acid, vitamin D and resveratrol alone and in combination with adenosine analogues on methylation and expression of phosphatase and tensin homologue tumour suppressor gene in breast cancer cells.Hypomethylation and induction of retinoic acid receptor beta 2 by concurrent action of adenosine analogues and natural compounds in breast cancer cells.Silencing of Wnt-1 by siRNA induces apoptosis of MCF-7 human breast cancer cells.Effects of anthracycline derivatives on human leukemia K562 cell growth and differentiation.Alternating expression levels of WWOX tumor suppressor and cancer-related genes in patients with bladder cancer.Constitutive telomerase activity in cells with tissue-renewing potential from estrogen-regulated rat tissues.Evaluation of oestrogen receptor expression in breast cancer by quantification of mRNA.WWOX--the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis.Markers of epithelial-to-mesenchymal transition reflect tumor biology according to patient age and Gleason score in prostate cancer.Predictive values of Notch signalling in renal carcinoma.The WWOX tumor suppressor gene in endometrial adenocarcinoma.Genetic alterations of WWOX in Wilms' tumor are involved in its carcinogenesis.Telomerase and cell proliferation in mouse skin papillomas.GADD45A and EPB41 as tumor suppressor genes in meningioma pathogenesis.Ki-67 expression in operable breast cancer: a comparative study of immunostaining and a real-time RT-PCR assay.Tumor Suppressor Gene in Breast Cancer, a Historical Perspective and Future DirectionsThe biological characteristics of transcription factors AP-2α and AP-2γ and their importance in various types of cancersA Novel Set of WNT Pathway Effectors as a Predictive Marker of Uterine Corpus Endometrial Carcinoma-Study Based on Weighted Co-expression MatricesSuppression of cell proliferation and telomerase activity in 4-(hydroxyphenyl)retinamide-treated mammary tumorsHigh activity of rituximab combined with cladribine and cyclophosphamide in a patient with pulmonary lymphomatoid granulomatosis and bone marrow involvementPrimary cutaneous marginal zone B-cell lymphoma in a patient with chronic lymphocytic leukaemiaPrimary osseous rhabdomyosarcoma with focal matrix formation mimicking osteosarcomaCyclin E expression in operable breast cancer quantified using real-time RT-PCR: a comparative study with immunostainingAnalysis of the expression of angiotensin II type 1 receptor and VEGF in endometrial adenocarcinoma with different clinicopathological characteristics
P50
Q28207184-CB7962E8-CD1D-454A-B7C9-840F06D9682FQ30165283-3478EE35-96D4-4F13-967C-BE67379192AFQ33518022-4A8129E4-FA6C-4939-B63A-5CDD77712698Q33864102-A4781A3E-7BC4-4BBA-AEDE-2A22C2201D4EQ34309523-ECDA6353-FAF9-42CF-A1E6-3C79D4115A8AQ34376564-9757325D-4740-4728-9522-0DE1905AD37DQ36065424-3E93A5C9-193D-4B52-8C56-8EF081628229Q36357862-B7C21B28-4812-48D3-9A50-1EB976CD95D1Q37071040-D8A23A18-FF61-4F4A-BE55-2E35D40615FDQ37334872-6B59A71C-A48C-4E2D-8A48-299F8C0E391DQ37553782-1443D613-4B80-46E4-927D-0087A41C8EB8Q37701529-8CAD7396-E2C8-4990-8CF4-2E910D62DC25Q38798793-871D3456-E478-4F9D-A8B7-EC0E5F665706Q38884820-2A732280-FFAF-4A65-B368-DE4E820E9ACCQ38912175-BAD6F65B-BEFD-46F4-8CD8-7B46F880FEA4Q38972730-BFD76729-1383-4468-99EE-CCF080D31531Q39498483-20A86D46-3485-4607-B92F-7B70B0092557Q39706990-24D0AD8F-EE7D-410D-BF8D-19A75EAB4D28Q40039839-6A8930A4-F60A-4867-BBDD-9D570900AAA3Q40368869-68F20B96-2BC5-47AE-83F4-B66731A7BF48Q42049504-DC9B73C0-9C8D-49FD-A291-A91FEBEA496FQ42450927-C1A10B67-17C1-48AA-AE71-09575115FC20Q42521871-A71FEEB3-24AF-434F-B1C4-2654C3D2954AQ45889262-1498A28E-9936-4899-8D0D-D5AF2C143932Q47177430-CD2A4A0F-32BE-4C22-B05F-CF671BBBA329Q47221055-7218B876-A99B-407B-90FC-59D775F96082Q53086559-12AB059E-1130-482B-9C5D-573D1ABD6420Q53154335-6717EB32-F66E-45D8-8FB5-E5CD161A03B3Q53438316-D8FA8722-718B-45FA-9048-F4867D9B43F8Q53657602-7DE6683F-EE85-4348-8A3B-69ACF023A0A7Q54603235-4D3E1FA8-C375-4065-B0FC-4D6205B4946FQ57107482-F310A0E0-566E-463C-A9D0-38285237EAB5Q64085553-2DAAECE3-E980-4384-A7A1-FC548D06692BQ64263671-FC6071C4-DCDB-4003-AAEF-8FA46B1400B0Q77765719-7D7606AC-1B9C-4FA6-AE1A-FB243301EBDBQ80243150-1D615030-E0C6-4092-928B-4B301B6BF5A9Q80792936-5A4D78D7-DBDE-4DE6-81F7-BF415A7BC6B2Q81373956-9362CC2D-E759-4F27-8576-252A3B9D57B6Q82744840-ACDF070F-FEEA-4027-8E97-D37316DC9701Q82964119-38744A45-07F0-40C7-9C76-CEFB76810E31
P50
description
Polish molecular biologist
@en
Pools onderzoeker
@nl
bitheolaí móilíneach Polannach
@ga
cercetător polonez
@ro
chercheur polonais
@fr
investigador polaco
@es
investigador polaco
@gl
investigador polonès
@ca
polnischer Forscher
@de
polski biolog molekularny
@pl
name
Andrzej Bednarek
@ast
Andrzej Bednarek
@ca
Andrzej Bednarek
@de
Andrzej Bednarek
@en
Andrzej Bednarek
@es
Andrzej Bednarek
@fr
Andrzej Bednarek
@ga
Andrzej Bednarek
@gl
Andrzej Bednarek
@it
Andrzej Bednarek
@nl
type
label
Andrzej Bednarek
@ast
Andrzej Bednarek
@ca
Andrzej Bednarek
@de
Andrzej Bednarek
@en
Andrzej Bednarek
@es
Andrzej Bednarek
@fr
Andrzej Bednarek
@ga
Andrzej Bednarek
@gl
Andrzej Bednarek
@it
Andrzej Bednarek
@nl
altLabel
Andrzej Kazimierz Bednarek
@pl
prefLabel
Andrzej Bednarek
@ast
Andrzej Bednarek
@ca
Andrzej Bednarek
@de
Andrzej Bednarek
@en
Andrzej Bednarek
@es
Andrzej Bednarek
@fr
Andrzej Bednarek
@ga
Andrzej Bednarek
@gl
Andrzej Bednarek
@it
Andrzej Bednarek
@nl
P214
P101
P1153
7004028210
P1412
P1559
Andrzej Bednarek
@pl
P19
P21
P214
P27
P31
P3124
P496
0000-0002-4570-4154
P569
1958-04-06T00:00:00Z
P734
P7859
viaf-55846837